Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe
 

Value-Based Care

Orlando, FL—Chimeric antigen receptor (CAR) T-cell therapy is now approved as third-line treatment for patients with B-cell lymphomas and leukemias. For some patients, CAR T-cell therapy is a miracle therapy, extending survival and, in some cases, as a bridge to a potentially curative transplant. But at an estimated cost of $375,000 to $475,000 per person, many people have questioned the value of this treatment, and whether it can be delivered effectively to patients not enrolled in clinical trials.


Results 1 - 1 of 1